

# SURVIVAL BENEFIT WITH VEMURAFENIB IN 'BRAF' MUTATION POSITIVE MELANOMA: AREA UNDER THE CURVE BASED REANALYSIS

DI-063

S. FENIX-CABALLERO, J. Diaz-Navarro, M. Camean-Castillo, E.J. Alegre-del Rey, C. Palomo-Palomo, M.A. Blanco-Castaño, J.M. Borrero-Rubio, M.J. Gandara-LadronDeGuevara<sup>1</sup>, J.C. GarciaDeParedes-Esteban<sup>1</sup>, D. Gil-Sierra<sup>1</sup>.

Puerto Real University Hospital, Spain

## BACKGROUND

McArthur et al. (1) recently reported the results of vemurafenib in BRAF mutation-positive melanoma vs. dacarbazine. Difference between medians in overall survival (OS) was 3.9 months (13.6 vs. 9.7, respectively).

**However, given the shape of the curves, difference in median survival (DMS) may not provide a good estimate of the survival benefit.**

(1) McArthur GA, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol.* 2014;15(3):323-32.

## PURPOSE

To **reanalyze** the survival benefit of vemurafenib in melanoma from the OS curves using an area-under-curves (AUC) based method.

## MATERIALS AND METHODS

Kaplan-Meier OS curve

### METHOD

According to a previously published method


**GRAPHICAL AUC**

Graphical AUC was applied compared to DMS.

AUC method quantifies the difference between areas, and the results are expressed in time units.

Alegre-DelRey E.J., et al. Area-based measures for assessing survival benefit in Kaplan-Meier's curves. *ESMO Congress, Amsterdam 2013.* URL: <http://eccamsterdam2013.ecco-org.eu/scientific-programme/searchable-programme.aspx#anchorScpr> (accessed 14/10/2014).

## RESULTS



Number at risk	0	3	6	9	12	15	18
Vemurafenib	337	326	280	231	178	109	44
Dacarbazine	338	244	173	111	79	50	24

▪ **63%** patients analysed

▪ **18 months** of follow-up

▪ **Remaining 44 and 24 patients** at risk in vemurafenib and dacarbazine group, respectively.

AUC-method:  
**OS=2.77 months**  
(9.45 vs. 6.68)

DMS (article):  
**OS= 3.9 months**  
13.6 vs. 9.7

**There is a gap of 1.13 months between both methods**

## CONCLUSIONS

AUC-based analysis showed a shorter survival benefit than the difference in median survival.

This is probably related to the shape of the curves, which diverged at the medium zone of the graph.

This may have implications on cost-effectiveness of treatment in a scenario of BRAF mutation-positive melanoma.